Analytical ultracentrifuge with absorbance and interference optics.
具有吸光度和干涉光学器件的分析超速离心机。
基本信息
- 批准号:10177341
- 负责人:
- 金额:$ 38.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAreaAutophagocytosisBiological ProcessBiophysicsCell surfaceCharacteristicsCollaborationsCore FacilityDoctor of PhilosophyEnzymesFacultyFee-for-Service PlansFeesFundingGPR3 geneGTP-Binding Protein alpha Subunits, GsHeterogeneityLipidsLongevityMaintenanceModelingMolecular ConformationNorth DakotaOpticsPharmacologyProductivityRadialRegulationResearchResearch PersonnelSamplingScientistShapesSignal TransductionSupervisionTimeUnited States National Institutes of HealthUniversitiesWagescollegeheme ainstrumentinstrumentationmacromoleculeprotein protein interactionservice providersstudent trainingsugartraining opportunity
项目摘要
PROJECT SUMMARY/ABSTRACT
Funds to purchase an Analytical Ultracentrifuge (AUC), model Beckman Couture Optima AUC, are
being requested. This state-of-the-art instrument will expand the research capabilities of a core number of NIH
funded investigators at North Dakota State University (NDSU). The AUC will allow characterization of
macromolecules in solution to obtain quantitative details on the size, shape, heterogeneity, conformation, and
assembly dynamics of these samples. This biophysical information provides critical information to understand
the activation, inhibition, overall regulation, and general function of biological processes. The chosen
instrument has both interference and absorbance optics allowing for the characterization of a broad range of
sample types, including sugars and lipids that do not have characteristic absorbance coefficients. Currently,
NDSU does not have this instrumentation and there is no AUC within a 200 mile radius. Therefore, users are
currently relying on access to an AUC via long distance collaboration or for fee service providers. This can be
inefficient and/or prohibitively expensive for investigators. The instrument will be housed in a core facility
managed by a full time Ph.D. scientist, supported by NDSU and whose salary is not dependent on user fees.
Thus, access and maintenance of the instrument will have direct supervision protecting the longevity of the
instrument. Projects of immediate relevance that will be addressed involve 1) protein:protein interactions
involved in bacterial cell surface signaling, 2) understanding agonist/antagonist influence on protein:protein
interactions involve in a G-protein coupled receptor, 3) protein:protein interactions involved in autophagy
regulation, and 4) assembly dynamics of a heme utilizing enzyme. Overall, our user group represents
investigators in four departments across three colleges and the instrument will facilitate research in areas
related to pharmacology to materials. The presence of an AUC at NDSU will greatly enhance the research
directions of these and other projects of NIH relevance. It will significantly increase student training
opportunities and research productivity of faculty.
项目摘要/摘要
购买分析超速离心机(AUC)的资金,型号为Beckman Couture Optima AUC
被请求了。这一最先进的仪器将扩大NIH核心数量的研究能力
北达科他州立大学(NDSU)资助的研究人员。AUC将允许对
溶液中的大分子,以获得有关大小、形状、异质性、构象和
这些样品的组装动力学。这些生物物理信息提供了重要的信息
生物过程的激活、抑制、整体调节和一般功能。被选中的
仪器同时具有干涉光学和吸收光学,从而能够表征大范围的
样品类型,包括没有特征吸收系数的糖和脂。目前,
NDSU没有这种仪器,半径200英里内也没有AUC。因此,用户是
目前依赖通过远程协作或付费服务提供商访问AUC。这可以是
对于调查人员来说,效率低下和/或昂贵得令人望而却步。仪器将被安置在一个核心设施中
由NDSU支持的全职博士科学家管理,他们的工资不依赖于用户费用。
因此,仪器的访问和维护将受到直接监督,以保护仪器的寿命
乐器。将解决的直接相关的项目涉及1)蛋白质:蛋白质相互作用
参与细菌细胞表面信号传递,2)了解激动剂/拮抗剂对蛋白质的影响:蛋白质
相互作用涉及G蛋白偶联受体,3)蛋白质:与自噬有关的蛋白质相互作用
调节,以及4)利用酶的血红素的组装动力学。总体而言,我们的用户组代表
三所大学四个系的研究人员,该仪器将促进各领域的研究
与药理学有关的材料。NDSU的AUC的出现将极大地促进研究
这些项目和其他与NIH相关的项目的方向。它将显著增加对学生的培训
教师的机会和研究效率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher L Colbert其他文献
Christopher L Colbert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher L Colbert', 18)}}的其他基金
Structural basis for cell surface siganling by a Gram-negative bacteria sigma-regulator
革兰氏阴性菌西格玛调节器细胞表面信号的结构基础
- 批准号:
9789675 - 财政年份:2018
- 资助金额:
$ 38.44万 - 项目类别:
Structural basis for cell surface siganling by a Gram-negative bacteria sigma-regulator
革兰氏阴性菌西格玛调节器细胞表面信号的结构基础
- 批准号:
10004679 - 财政年份:2018
- 资助金额:
$ 38.44万 - 项目类别:
Structural basis for cell surface siganling by a Gram-negative bacteria sigma-regulator
革兰氏阴性菌西格玛调节器细胞表面信号的结构基础
- 批准号:
10387865 - 财政年份:2018
- 资助金额:
$ 38.44万 - 项目类别:
Structural basis for cell surface siganling by a Gram-negative bacteria sigma-regulator
革兰氏阴性菌西格玛调节器细胞表面信号的结构基础
- 批准号:
10240569 - 财政年份:2018
- 资助金额:
$ 38.44万 - 项目类别:
Mechanism of inner membrane sigma-regulator function in Gram-negative bacteria
革兰氏阴性菌内膜西格玛调节功能的机制
- 批准号:
9316212 - 财政年份:2015
- 资助金额:
$ 38.44万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:














{{item.name}}会员




